AbbVie (ABBV) Reports In-Line Q4 Earnings, Revenues Miss

A generic image of a stock chart.
Credit: Shutterstock photo

North Chicago, IL-based AbbVie Inc.ABBV is best known for its autoimmune disease drug, Humira. Other key products include Imbruvica (cancer) and Viekira Pak (hepatitis C virus (HCV) treatment).

Humira, the company's flagship product which is approved for a wide range of indications, is a major contributor to AbbVie's top line. While Humira will remain the key growth driver at AbbVie, the coming quarters will see investor focus remaining primarily on Viekira's performance as well as pipeline updates.

Meanwhile, the Pharmacyclics acquisition has diversified AbbVie's product portfolio with the addition of Imbruvica.

AbbVie's performance has been mixed, with the pharmaceuticals company delivering positive surprises in the two of the past four quarter while recording in-line earnings in the other two. The average earnings beat over the last four quarters is 1.92%.

AbbVie Inc. Price

AbbVie Inc. Price | AbbVie Inc. Quote

Currently, AbbVie has a Zacks Rank #3 (Hold), but that could definitely change following the company's earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:

Earnings: AbbVie's fourth-quarter earnings came in at $1.20 per share, in-line with the Zacks Consensus Estimate.

Revenues: AbbVie posted revenues of $6.80 billion, missing the Zacks Consensus Estimate of $6.92 billion.

Key Stats: Humira sales came in at $4.3 billion. Fourth-quarter Imbruvica sales were $511 million. Viekira sales were $311 million in the fourth quarter.

2017 Outlook: AbbVie provided its outlook for 2017. The company expects adjusted EPS in the range of $5.44-$5.54. The Zacks Consensus Estimate is currently pegged at $5.48 per share.

Check back later for our full write up on this AbbVie earnings report.

The Best Place to Start Your Stock Search

Today, you are invited to download the full, up-to-the-minute list of 220 Zacks Rank #1 "Strong Buy" stocks - absolutely free of charge. Since 1988, Zacks Rank #1 stocks have nearly tripled the market, with average gains of +26% per year. Plus, you can access the list of portfolio-killing Zacks Rank #5 "Strong Sells" and other private research. See these stocks free >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

AbbVie Inc. (ABBV): Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Other Topics

Earnings Investing Stocks

Latest Markets Videos


    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at

    Learn More